ArticleParasites & vectors2025
TAF15 mediates ROP16-induced apoptosis and cell cycle arrest in lung cancer.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThis study aimed to investigate the effects of the interaction between ROP16 and TAF15 on apoptosis and cell cycle regulation in A549 lung adenocarcinoma cells.
methodsLentivirus-infected A549 cells which could overexpress type I, II, and III ROP16, along with an empty vector control group, were established. Potential interacting proteins with ROP16 were identified by using co-immunoprecipitation (Co-IP) and liquid chromatography-mass spectrometry (LC-MS). High-scoring interacting proteins were selected for verification through Venn diagram analysis, scoring, and intensity evaluation. The interaction between ROP16 and TAF15 was confirmed by using co-immunoprecipitation. Moreover, TAF15-specific siRNA was synthesized and transfected into A549 cells overexpressing ROP16 types I, II, and III. The levels of apoptosis and cell cycle were detected by flow cytometry (FCM), and the expression levels of apoptosis-related proteins and cell cycle-related proteins were detected by real-time fluorescence quantitative PCR (RT-qPCR) and western blotting.
resultsThree stable A549 cell lines overexpressing type I, II, and III ROP16 were successfully established. IP-LC/MS identified 29 potential ROP16-interacting proteins, among which 13 had a score greater than 100. Subsequent bioinformatic analysis and co-immunoprecipitation confirmed the interaction between ROP16 and TAF15. Flow cytometry analysis revealed that type I and III ROP16 promoted A549 cell apoptosis and induced cell cycle arrest. Furthermore, western blotting and RT-qPCR demonstrated their modulation of the expression of cell cycle regulators (p21, CDK6, Cyclin D1) and apoptosis-related proteins (Bax, BCL-2, p53, Caspase-9). In contrast, type II ROP16 exhibited none of these effects. However, upon TAF15 silencing, the pro-apoptotic effects of type I and III ROP16 were attenuated, no significant cell cycle arrest was observed, and their regulatory effects on the expression of cell cycle- and apoptosis-related proteins were also significantly diminished.
conclusionsOur study demonstrates that type I/III ROP16 induce apoptosis and cell cycle arrest in A549 cells through interactions with the host RNA-binding protein TAF15. These findings not only provide compelling evidence for the oncosuppressive potential of Toxoplasma gondii-derived secretory proteins but also uncover a previously unrecognized mechanism by which parasite effectors hijack host transcriptional regulators to subvert cancer cell survival pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.